Castleman-Kojima disease
MONDO:0018702A clinicopathologic variant of multicentric Castleman's disease characterized by thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly
Also known as: TAFRO syndrome, thrombocytopenia-anasarca-fever-renal insufficiency-organomegaly syndrome
83 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
HPV vaccine shows promise for girls on Immune-Suppressing drugs
⭐️ VACCINE ⭐️ CompletedThis study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:36 UTC
-
New booster aims to shield the vulnerable from COVID-19
⭐️ VACCINE ⭐️ CompletedThis study tested an extra dose of the HIPRA COVID-19 vaccine in 241 adults with conditions like HIV, kidney disease, or autoimmune disorders that weaken the immune system. The goal was to see if the booster raises antibody levels against virus variants and remains safe. Research…
Phase: PHASE2, PHASE3 • Sponsor: Hipra Scientific, S.L.U • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 18:38 UTC
-
New antibody replacement therapy aims to shield vulnerable patients from serious infections
Disease control CompletedThis study tests a new intravenous immunoglobulin (IGIV) called PlasmaCap IG in adults and children aged 2 to 70 with primary immune deficiency diseases (PIDD). Participants receive regular infusions of the therapy for 12 months. The goal is to see if it prevents serious bacteria…
Phase: PHASE3 • Sponsor: Evolve Biologics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug shows promise for long-term immune deficiency treatment
Disease control CompletedThis study checked the long-term safety of TAK-771 in 15 Japanese patients with primary immunodeficiency disease (PID). Participants received TAK-771 injections for up to 3 years. The main goal was to monitor side effects and immune reactions. The study is now complete.
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New antibody infusion shows promise for immune deficiency patients
Disease control CompletedThis study tested a new intravenous immunoglobulin (IVIg) treatment called Kedrion IVIg 10% in 47 people with primary immunodeficiency, a condition where the immune system cannot make enough antibodies. The goal was to see if regular infusions of this antibody therapy could preve…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug VIS171 tested in humans for first time – could it tame autoimmune disease?
Disease control CompletedThis early-phase trial tested a new drug called VIS171 in 61 people: first in healthy volunteers, then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. No results on whether it actually helps the disease are available ye…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New shot option for immune deficiency shows promise in early trial
Disease control CompletedThis study tested a new medicine called TAK-881, a concentrated antibody solution given under the skin, in 65 people with primary immunodeficiency diseases (PIDD). The goal was to see how well the body absorbs it and if it is safe compared to an existing treatment (HYQVIA). Parti…
Phase: PHASE2, PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New chemo combo may lower death risk in child stem cell transplants
Disease control CompletedThis study tested two different chemotherapy drugs (Treosulfan and Busulfan) given before a stem cell transplant in 106 children with serious non-cancer diseases like immune disorders, metabolic diseases, blood disorders, and bone marrow failure. The goal was to see which drug le…
Phase: PHASE2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Blood filter shows promise for autoimmune patients
Disease control CompletedThis study looked at a device called GLOBAFFIN that filters antibodies from the blood to help people with autoimmune diseases. It involved 34 adults and measured how much harmful antibodies were removed and if patients felt better. The goal was to see if the device is safe and wo…
Phase: NA • Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
Cutting salt and sugar may tame steroid side effects
Symptom relief CompletedThis study looked at whether a diet low in salt and sugar can reduce common side effects of corticosteroid treatment, such as weight gain, high blood pressure, and diabetes. Fifty adults with autoimmune diseases or asthma who were starting high-dose corticosteroids were randomly …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Scientists hunt for genetic and environmental triggers of rare muscle diseases
Knowledge-focused CompletedThis study looked at 719 people, including patients with autoimmune connective tissue diseases like myositis, their blood relatives, and healthy volunteers. Researchers collected blood samples and medical histories to find genetic and environmental factors that may trigger these …
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive study reveals COVID-19 risks for autoimmune patients
Knowledge-focused CompletedThis study looked at over 13,000 people with chronic inflammatory rheumatism or autoimmune diseases who had or were suspected to have COVID-19. Researchers tracked how many developed severe COVID-19 requiring intensive care or leading to death. They also examined risk factors lik…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Tiny study hunts for hidden genes behind immune failures
Knowledge-focused CompletedThis study analyzed DNA from 9 patients with primary immune deficiencies whose genetic cause was unknown. Researchers used whole exome or genome sequencing to look for new mutations that might explain their condition. The goal was to identify new inborn errors of immunity, which …
Sponsor: University of Zurich • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Are hidden immune defects causing your recurring infections? new study investigates.
Knowledge-focused CompletedThis study looked for hidden immune system problems in adults who get frequent or severe bacterial infections, like pneumonia or meningitis. Researchers screened 120 adults aged 18-65 to see how many had an undiagnosed primary immunodeficiency. The goal was to find out if these c…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Rituximab infection risk under the microscope
Knowledge-focused CompletedThis completed study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab. The goal was to track how many developed serious infections and to understand what factors increase that risk. Researchers …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New study sheds light on pregnancy risks for women with rare immune disorders
Knowledge-focused CompletedThis study looked at 99 women with primary immune deficiency to learn more about their pregnancies and birth outcomes. Researchers tracked infections during pregnancy and after birth, as well as how well contraception worked. The goal is to help doctors give better advice to wome…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Immunotherapy side effects under the microscope: new study monitors autoantibodies
Knowledge-focused CompletedThis completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New drug LAD191 tested for safety in autoimmune patients
Knowledge-focused CompletedThis early-phase study tested the safety and tolerability of a new drug called LAD191 in 69 healthy adults and people with an autoimmune disease. Researchers gave single or multiple doses to see how the body processes the drug and if it causes side effects. The goal was to gather…
Phase: PHASE1 • Sponsor: Almirall, S.A. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Scientists gather clues on mysterious immune defects
Knowledge-focused CompletedThis study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Epidural safety checked for moms with rare immune disorders
Knowledge-focused CompletedThis study looked at whether epidural or spinal anesthesia during childbirth leads to more infections in women with primary immunodeficiencies (weak immune systems). Researchers tracked 30 women from a national registry for 28 days after delivery to see if they developed serious …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:52 UTC